SEC Form 4 · accession 0001144204-15-058985

Spark Therapeutics, Inc. · ONCE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Anand Mehra

Director

Period of report

Oct 7, 2015

Accepted (ET)

Oct 9, 2015 · 7:59 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001609351

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F7	Oct 7, 2015	S	85,502	$45.56	D	2,033,074	I	See footnote
Common Stock^F2,F7	Oct 7, 2015	S	153,008	$46.23	D	1,880,066	I	See footnote
Common Stock^F3,F7	Oct 7, 2015	S	13,402	$47.14	D	1,866,664	I	See footnote
Common Stock^F4,F7	Oct 8, 2015	S	120,593	$44.38	D	1,746,071	I	See footnote
Common Stock^F5,F7	Oct 8, 2015	S	145,723	$45.27	D	1,600,348	I	See footnote
Common Stock^F6,F7	Oct 8, 2015	S	11,316	$46.38	D	1,589,032	I	See footnote

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.99, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (6) to this Form 4.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.00 to $46.99, inclusive.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.80, inclusive.
F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.00 to $44.96, inclusive.
F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.99, inclusive.
F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.03 to $46.85, inclusive.
F7The securities are owned directly by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII"), the general partner of SVP VIII, and Anand Mehra, a director of the Issuer, James I. Healy, Srinivas Akkaraju, and Michael Powell, the managing members of SM VIII, may be deemed to have shared voting and dispositive power over the shares owned by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares owned by SVP VIII except to the extent of any pecuniary interest therein.